AstraZeneca Enhertu Secures US FDA Approval for HER2-Low Breast Cancer
The US Food and Drug Administration (FDA) has approved Enhertu of AstraZeneca and Daiichi Sankyo for the treatment of adult patients with metastatic HER2-low breast cancer, who have received a prior chemotherapy in the metastatic setting during six months of completing adjuvant chemotherapy. Enhertu is a specifically designed HER2-directed antibody drug conjugate (ADC), that has […]
Continue Reading